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OBJECTIVES: To examine cost-effectiveness of oral triptan medications in Korea, 
and inform policymakers which triptan has the best/least value for money. METHODS: 
We conducted literature reviews to identify economic and clinical values of triptan 
therapy. The clinical value of triptans was estimated based on randomized controlled 
trials (RCT), systematic reviews, and meta-analyses. We refer to previously published 
economic evaluation studies of triptan medications for selection of outcome measures 
and design of the simulation model. We built a decision tree model to explore cost-
effectiveness of treating single attack in migraine patients. Outcome measures were 
2-hour pain free, sustained freedom from pain, and sustained freedom from pain 
without side effects, based on previous studies and clinical practice guidelines. Cost 
of treating migraine was estimated by using Korea’s national health insurance claims 
database. Societal perspective was taken. One-way sensitivity analyses, as well as 
probabilistic sensitivity analyses, were conducted. RESULTS: Naratriptan, Sumatrip-
tan, and Zolmitriptans are listed in the Korean National Health Insurance Drug List 
as of 2007. The efﬁ cacy of Naratriptan is inferior to Sumatriptan and Zolmitriptan 
in terms of 2-hour pain free, sustained freedom from pain, and sustained freedom 
from pain without adverse events. Cost-effectiveness analysis suggests that Naratrip-
tan and Zolmitriptan are dominated by Sumatriptan in terms of the three observed 
outcome measures. Sensitivity analyses suggest that our results were robust under 
different assumptions. CONCLUSIONS: Naratriptan and Zolmitriptan are dominated 
by Sumatriptan in terms of 2-hour pain free, sustained freedom from pain, sustained 
freedom from pain without side effects. Our results should be interpreted with caution, 
since Naratriptan and Zolimitriptan may have other values which could not be mea-
sured in our study. 
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes 
Studies
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OBJECTIVES: Hemophilia care in China is at a nascent stage and efforts to improve 
care require a better understanding of current treatment standards, clinical outcomes, 
and patient health-related quality of life (HRQOL) in China relative to other countries. 
METHODS: Severe hemophilia A patients and their caregivers in China (Beijing and 
Shanghai), Russia, Argentina, and the United States completed a cross-sectional survey 
of treatment and health outcomes in 2009. HRQOL was measured using the PEDS-QL 
for children, the SF-12 for adults and the EQ-5D for all patients. [Due to recruitment 
methods, the Chinese patient cohort may not be representative of the average Chinese 
hemophilia patient.]. RESULTS: A total of 160, 167, 57, and 117 patients in China, 
Russia, Argentina and the United States completed the survey, respectively. On 
average, while Russian, Argentine, and American patients reported being diagnosed 
within the ﬁ rst year after birth, Chinese patients waited 6 years. Only 18% of the 
Chinese patients are able to receive FVIII to treat bleeds all of the time, while it is 
53%, 86% and 91% for Argentina, Russia and the United States (chi-square P < 
0.0001). Chinese hemophilia children scored an average of 38.4 on the physical 
functioning domain of the PEDS-QL; signiﬁ cantly lower than Argentina (61.5), Russia 
(60.6) and the United States S (82.9) (all P < 0.0001). Chinese hemophilia adults 
reported an average of 33.9 on the SF-12 physical component summary which was 
signiﬁ cantly lower than patients in Argentina (39.3), Russia (37.4) and the United 
States (39.8) (all P < 0.01). The average EQ-5D health utility score was signiﬁ cantly 
lower in China (0.49) compared with 0.75, 0.73 and 0.80 in Argentina, Russia and 
the United States, respectively (all P < 0.0001). CONCLUSIONS: There is substantial 
room to improve the HRQOL for Chinese hemophilia patients. Improving access to 
hemophilia care and Factor VIII treatment may improve health outcomes and thus 
HRQOL. 
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OBJECTIVES: Impact of chronic immune thrombocytopenic purpura (ITP) and its 
treatments on quality of life (QoL) was explored. METHODS: As the modiﬁ ed genera-
tive round, a questionnaire composed of 29 items was developed through literature 
review and focus group discussion. Then 2-round web based delphi survey was con-
ducted with 11 panelists who were key hematologists and treating most of the ITP 
patients in Korea. The panelists were asked to make a choice on main discomforts 
that generally affect ITP patients’ QoL and rate the health of non-refractory and 
refractory patients using EQ5D and VAS. Furthermore, they were requested to indi-
cate their level of agreement on possible aspects of QoL, based on 5-point likert scale. 
RESULTS: The nearly unanimous consensus was made that major factors affecting 
QoL were consistent bruising, limitation of physical & social activities and psychologi-
cal distress at bleeding risk. The utility derived from rated QoL for non-refractory ITP 
was 0.717 for EQ5D and 56.4 for VAS and that for refractory ITP was 0.422 for 
EQ5D and 47.7 for VAS. The considerable impairment of QoL was ﬁ gured out for 
overall chronic ITP patients compared with general population and the decrement of 
QoL for refractory patients was found far more serious than non-refractory patients 
(Mean difference of 0.295 for EQ5D). It was also concluded that economic burden 
from non-reimbursement drug uses was signiﬁ cant determinants of diminution of 
QoL, in addition to increased risk of bleeding and cumulated side effects from tryouts. 
CONCLUSIONS: ITP and its treatments negatively impact on QoL and most seriously 
in refractory patients. The treatment that effectively prevents and manages refractory 
ITP would beneﬁ t health-related QoL in chronic ITP patients. 
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OBJECTIVES: This study is aimed to descriptively analyze the treatment strategies of 
neuropathic pain (NeP) in a pain specialist setting. METHODS: A retrospective 
medical chart review for 266 new NeP patients attending the pain clinic in Siriraj 
hospital, a tertiary care hospital, over a period of 18 months (January 2008–June 
2009) was performed. Collected data included patient characteristics, comorbidities, 
types of NeP, and the use of pharmacological and non-pharmacological treatments. 
RESULTS: Patients were predominantly female (57.1%) with a mean age of 56 years. 
Mixed NeP was found to be the most common NeP (60.9%) whereas pure NeP 
accounted for 39.1%. Over two-thirds of the patients (79.3%) were newly diagnosed 
at the pain clinic, and a small proportion were diagnosed and referred from other 
hospital departments (17.3%) and other hospitals (3.4%). Common comorbidities 
were musculoskeletal disorder (32.7%), malignancy (29.3%) while hypertension and 
diabetes were less frequently found. Opioids (O) (29.5%) and anti-epileptic drugs (E) 
(28.8%) represented the majority of drugs used whereas the use of antidepressants 
(D) and NSAIDs accounted for 18.4% and 10.6% respectively. Intervention for pain 
relief was prescribed at 1.7%. In mixed NeP, O were the most common drug (32.9%) 
while E were most often prescribed in pure NeP (33.0%). We found the three-drug 
combination (O + E + D) was the most common (37.8%) treatment strategy. The 
four-drug combination (O + E + D + NSAIDs) was the second most common strategy 
(33.0%). The two-drug combination (O + E) and single drug (E) accounted for 14.8% 
and 3.4% respectively. Considering the type of NeP, the most prevalent treatment 
strategy in pure NeP and mixed NeP was the three-drug combination (44%) and the 
four-drug combination (36.2%) respectively. CONCLUSIONS: NeP treatment strate-
gies using more than two drugs from different therapeutic areas were commonly used 
in the pain specialist setting. This is due to pain symptoms in NeP being complex and 
frequently associated with other comorbidities. 
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: To compare the risk of death between peritoneal dialysis (PD) and 
hemodialysis (HD) patients. METHODS: Through the national health-care insurance 
(NHI) database, we identiﬁ ed a national cohort of 66,080 patients initiating dialysis 
therapy between January 1, 1998 and December 31, 2006 and followed a maximum 
of 9 years. To compare the survival functions between PD and HD patients, the 
Kaplan-Meier life table was applied. Both proportional and non-proportional Cox 
regression models were conducted to evaluate the relative hazard of death by dialysis 
modality using the intention-to-treat (ITT) approach. Three propensity score strategies 
were applied to achieve covariate balance, matching, stratiﬁ cation, and regression 
adjustment. Subsets analyses were deﬁ ned by age and diabetes mellitus (DM), and 
sensitivity analyses were conducted by the logit propensity score. RESULTS: The 
results showed that the hazard ratios (HRs) of PD and HD patients varied by age and 
with/without DM. Among patients under age 49 with or without DM, PD was associ-
ated with a lower risk of death. Among patients aged 50–59, the HR of PD relative 
to HD was higher for those with DM but was lower for those without DM. For 
patients aged over 60 with or without DM, the HRs were higher on PD than on HD. 
We also found that the HRs for PD and HD were not proportional over time. The 
risk of death for PD patients was generally lower during the ﬁ rst year or ﬁ rst 2 years 
